Aardvark Therapeutics
Market cap $25.2M 21.9M shares (10-Q, Nov 2, 2026) × $1.15 close Nov 17, 2026
Most recent annual filing: 2026-03-23
- ARD-101 FDA feedback1Q 2027ARD-101 FDA feedback, 1Q 2027, material
- ARD-101 trial start2027ARD-101 trial start, 2027, material
- AARD retention letters corporate updateJan 1, 2027AARD retention letters corporate update, Jan 1, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Discontinued (2)
- ARD-201 — Obesity · voluntary pause pending further guidance; related to cardiac observations in ARD-101 healthy volunteer trial
- ARD-101 — Hypothalamic Obesity · delayed indefinitely to direct more resources to ARD-201
Capital (as filed)
- Cash
- $60.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $13K Sep 30, 2026
- Operating cash flow
- −$13.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $60.3M cash, runway through 2027 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-14 UPDATE: Aardvark Therapeutics (AARD) - The Checkpoints Land 🔒 Paid
- 2026-11-02 Aardvark Therapeutics (AARD) - Scientific Deep Dive for ARD-101 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Aardvark Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-11-02 Avoid Aardvark Therapeutics (AARD) - Scientific Deep Dive for ARD-101 and Pipeline Products HERO produced no randomized efficacy signal at any visit, the only positive signals come from open-label and unrandomized reads, and the stock's discount to cash reflects management's plan to spend that cash rather than a mispricing of the science.
- 2026-11-14 Avoid UPDATE: Aardvark Therapeutics (AARD) - The Checkpoints Land Q3 cash confirmed as expected and options reset, but the only FDA-approved next step is an open-label trial that cannot demonstrate efficacy, and none of the WATCH LIST triggers has been met.
- Avoid call · opened Nov 2, 2026 at $1.20 · -4.2% vs XBI -4.5% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Following the lifting of the clinical hold, Aardvark requested a meeting with the FDA, which has been scheduled for the first quarter of 2027, to discuss its proposed clinical development plan for ARD-101 in PWS.”
matched to ARD-101 · regulatory submission
-
-
-
“Following the lifting of the clinical hold on ARD-101 by the FDA, we requested a meeting with the FDA, which has been scheduled for the first quarter of 2027, to discuss our proposed clinical development plan for ARD-101 for the treatment of hyperphagia in patients with PWS.”
matched to ARD-101 · regulatory submission
-
-
-
“We are conducting a comprehensive review of the data, including initiating the unblinding and analysis of program-wide data related to the partially completed HERO trial, developing additional clinical study protocols and evaluating updates to our program-wide safety strategy to support future discussions with the FDA regarding potential next steps for the ARD-101 clinical development program in PWS, and expect to provide further guidance in the third quarter of 2026.”
matched to ARD-101 · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 2026ReleaseAardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates→ BD updateSummary on the 8-K
- Nov 13, 20268-KCurrent report: results of operations · EX-99.1→ BD updateAardvark's Q3 10-Q puts the first hard cash number on the board post-HERO termination ($60.3M, ~$13.6M Q3 burn), schedules the FDA meeting for Q1 2027, and adds a mavacamten-era clinical strategist to the board — all while the stock shed 12.5% on the session.
- Nov 13, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 23, 20268-KCurrent report: other events · EX-99.1
- Oct 22, 20268-KCurrent report: other events · EX-99.1
- Oct 8, 20268-KCurrent report: officer / director change, other events · EX-99.1
- Aug 17, 20268-KCurrent report: shareholder vote
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jul 10, 2026DEF 14AProxy statement
- Jun 12, 20268-KCurrent report: officer / director change
- May 14, 20268-KCurrent report: other events · EX-99.1
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 3, 2026424B5Prospectus supplement (offering)
- Mar 24, 20268-KCurrent report: material agreement
- Mar 23, 2026S-3Shelf registration
- Mar 23, 20268-KCurrent report: results of operations · EX-99.1
- Mar 23, 202610-KAnnual report
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Jul 10, 2026ARSAnnual report to shareholders
- Jun 29, 2026PRE 14APRE 14A
- Apr 3, 2026EFFECTRegistration effective
- Mar 30, 2026CORRESPCORRESP
- Mar 25, 2026UPLOADUPLOAD
- Mar 24, 2026S-8Employee plan registration